Although age-adjusted mortality of coronary heart disease has been successfully reduced over recent years, coronary heart disease still represents a leading cause of death and morbidity, in particular in patients at very high cardiovascular risk. Dyslipidaemia plays a major and causal role in the development and clinical progression of coronary heart disease. At present, low-density lipoprotein cholesterol represents the primary target of lipid-directed therapies for the prevention of cardiovascular disease and events. The new European guidelines recommend intensive statin therapy and the possible addition of ezetimibe to reduce low-density lipoprotein cholesterol to a goal of less than 1.8 mmol/L (<70 mg/dL) or by at least 50% if the baseline low-density lipoprotein cholesterol is between 1.8 and 3.5 mmol/L (70-135 mg/dL) in patients at very high cardiovascular risk. Also, the new European guidelines now mention the potential use of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors in very high-risk patients with persistently high levels of low-density lipoprotein cholesterol despite maximally tolerated statin treatment in combination with ezetimibe or in patients with statin intolerance. A recent European consensus document discusses the practical clinical use of PCSK9 inhibitors and provides more detailed recommendations. However, despite the overwhelming scientific evidence of the beneficial effects of lipid-lowering therapies, a large proportion of patients at very high cardiovascular risk are not treated according to the current European guideline recommendations. Reinforcing lipid-lowering therapies provides an excellent chance effectively to reduce morbidity and mortality from coronary heart disease.
Introduction
Improved treatment of cardiovascular risk factors, as well as the establishment of a more effective therapeutic strategy in the setting of acute coronary syndromes (ACSs), have resulted in a decrease in age-adjusted mortality from coronary heart disease (CHD) 1 and reduced age-adjusted incidence of myocardial infarction. 2 However, cardiovascular disease remains the leading cause of premature death in western societies and most of these deaths are attributable to CHD. 3 The fact that increased low-density lipoprotein (LDL) cholesterol represents a causal risk factor for CHD is well accepted, based on experimental, clinical and genetic studies. 4 LDL cholesterol has emerged as the primary target in the treatment of dyslipidaemia, 5, 6 while, based on the failure of high-density lipoprotein (HDL) cholesterol-raising treatment strategies to reduce cardiovascular risk in recent studies, HDL cholesterol is not recommended to serve as a primary treatment target. 7 Randomised controlled prospective clinical trials have shown that, in patients with established cardiovascular disease, lowering of LDL cholesterol with statins reduces the risk of recurrent cardiovascular events. 8 US guidelines recommend a high-dose statin therapy in patients with CHD in order to achieve a reduction of LDL cholesterol by at least 50%, 6 whereas European guidelines recommend reducing LDL cholesterol to a goal of less than 1.8 mmol/L (<70 mg/dL) or by at least 50% if the baseline LDL cholesterol is between 1.8 and 3.5 mmol/L (70-135 mg/dL). 5 Both of these recommendations derive from the consideration that a cardiovascular protective effect of lowering LDL cholesterol is primarily determined by the absolute reduction of LDL cholesterol. Also, this protective effect is clearly not limited to statin therapy alone. The results of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) showed that more CHD patients can meet LDL cholesterol goals when treated with a combination of a statin and ezetimibe as compared to those patients treated with a statin therapy alone. After multivariable adjustment, this was associated with improved cardiovascular outcomes in those patients treated with the combination therapy. 9 Furthermore, substances such as monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 (PCSK9) and long-acting RNA interference agents inhibiting the synthesis of PCSK9 have been shown to lower LDL cholesterol substantially. [10] [11] [12] [13] Recently, the results of the Further Cardiovascular Outcome Research with PCSK9 Inhibition in Subjects with Elevated Risk trial (FOURIER) were published. The findings show, for the first time, that the inhibition of PCSK9, on a background of statin therapy, not only lowers LDL cholesterol, but also significantly reduces the risk of cardiovascular events 14 in patients at very high cardiovascular risk.
LDL cholesterol's causal role in the progression of CHD
LDL cholesterol is thought to initiate atherosclerotic plaques when it penetrates through the endothelium of a coronary artery into its wall. After being retained there, the lipids of LDL cholesterol become oxidised. Hereby, apolipoprotein B (apoB), a large protein surrounding the LDL particle, becomes modified. Scavenger receptors on macrophages recognise this modified apoB. Subsequently, endocytosis internalises apoB, converting the macrophages to foam cells. These lipid-rich foam cells initiate inflammation and, in response, smooth muscle cells in the arterial intima proliferate and produce collagen. The plaque can become unstable; it eventually ruptures, leading to thrombotic occlusion of the coronary artery causing ACS. 15 The significance of LDL cholesterol for the function of endothelial cells and monocytes and for the pathogenesis of CHD, respectively, has been investigated by studies using isolated endothelial cells as well as by animal studies. 16 Furthermore, epidemiological studies provide evidence that levels of LDL cholesterol correlate with the incidence of CHD and its progression, independent of sex, diabetes and body mass index. 17 The correlation between LDL cholesterol levels and the risk of CHD is particularly strong in younger people, but is seen in every age group. Also, this correlation is characterised by a log-linear relationship: a greater positive association is evident in higher levels of LDL cholesterol, while the association is weaker in lower levels of LDL cholesterol. 17 Studies using intravascular ultrasound (IVUS) directly and visually showed the correlation of LDL cholesterol levels and the resizing of coronary plaques. 18, 19 In a study with 60 patients, a positive linear relationship between levels of LDL cholesterol and the annual resizing of a coronary plaque was seen, with a LDL cholesterol level of 75 mg/dL predicting stability in plaque volume. 18 
Lowering LDL cholesterol with statin therapy reduces cardiovascular events
Since being commercially launched in the 1980s, LDL cholesterol-lowering inhibitors of HMG CoA reductase, known as statins, have, in addition to non-pharmaceutical lifestyle modification, become the gold standard therapy in preventing and treating CHD. Current guidelines recommend that statins should be used as first-line therapy in patients with dyslipidaemia. 5, 6 Remarkably consistent results of numerous randomised, double-blind, placebo controlled trials showed that lowering LDL cholesterol using a statin reduces cardiovascular events with no evidence for a lower threshold. [20] [21] [22] [23] In the Heart Protections Study (HPS), a total of 20,536 subjects were treated with simvastatin for 5 years. Interestingly, the relative risk reduction associated with the use of simvastatin was similar even throughout the subgroups of subjects with other risk factors for cardiovascular disease (diabetes, hypertension, smoking). 21 A meta-analysis of data from more than 100,000 participants in 26 randomised trials showed that further reducing LDL cholesterol by using more intensive statin regimens safely produces a further reduction of cardiovascular events. Each LDL cholesterol reduction of 1 vmmol/L (40 mg/dL) reduced the annual cardiovascular event rate by just over 20%. Across all 26 trials included in this meta-analysis, all-cause mortality was reduced by 10% if LDL cholesterol was reduced by 1 mmol/L (40 mg/dL). 8 The beneficial effect of lowering LDL cholesterol with statin therapy is not limited to individuals who are already at high risk of cardiovascular disease or those already suffering from cardiovascular disease.
Another meta-analysis of 22 statin trials involving 134,000 participants, also carried out by the Cholesterol Treatment Trialists' Collaborators, showed that, in low-risk individuals, cardiovascular events are reduced by 20% for each reduction of LDL cholesterol of 1 mmol/L (40 mg/dL). 24 Studies using IVUS when investigating the effect of a LDL cholesterol-lowering statin therapy on coronary plaques, as the pathomorphological correlate for ACS, concluded that a more intensive lowering of LDL cholesterol can lead to the regression of plaque volume when LDL cholesterol levels fall below 70 mg/dL. 25, 26 When choosing a statin for lowering LDL cholesterol it has to be taken into account that the degree of LDL cholesterol reduction is:
. dose dependent, but not linear (doubling the dose of a stain will further reduce LDL cholesterol by a mean of 6%); . variable between the different statins (with atorvastatin and rosuvastatin being the two most potent agents available); 27 and . interindividually variable with the same dose of drug. 28 
Additional options in lowering LDL cholesterol
Statins reduce cardiovascular risk by about 30-45%, but a substantial cardiovascular risk remains in a large proportion of patients, especially in those who do not reach LDL cholesterol treatment goals even on the maximum tolerated dose of statin therapy. 29 Also, the side effects of statin therapy such as statinassociated muscle symptoms are rare, but they become relevant by substantially reducing adherence to statin treatment and, consequently, statin side effects represent a strong predictor of failure to meet LDL cholesterol goals. 30, 31 These aspects have, among others, led to trials investigating additional LDL cholesterollowering therapeutic approaches and their effects on cardiovascular events.
Ezetimibe lowers LDL cholesterol through the inhibition of the Niemann-Pick C1-like 1 protein and consequent inhibition of cholesterol absorption. In IMPROVE-IT, ezetimibe was added to 40 mg of simvastatin in patients after ACS. The study had a median follow-up of 6 years. The median time-weighted average LDL cholesterol level during the study was 1.4 mmol/L (53.7 mg/dL) in the simvastatin-ezetimibe group, compared with 1.8 mmol/L (69 mg/dL) in the simvastatin-monotherapy group (P < 0.001). Significantly fewer endpoints (composite of cardiovascular death, non-fatal myocardial infarction, unstable angina requiring rehospitalisation, coronary revascularisation 30 days after randomisation, or non-fatal stroke) occurred in the simvastatin-ezetimibe group (P ¼ 0.016) with no evidence of adverse effects caused by further reducing LDL cholesterol. 32 These results support the concept that lowering LDL cholesterol, even by means other than statins, is beneficial and can be performed without harm. In conclusion, ezetimibe should be used as second-line therapy in association with statins when therapeutic goals are not achieved with the maximal tolerated statin dose (or alone in patients intolerant to statins or with contraindications to statins). 5 In 2003 Abifadel and colleagues reported for the first time a gain of function mutation of PCSK9 causing familial hypercholesterolaemia in a French family. 33 Furthermore, a loss of function mutation of PCSK9 was found in individuals with very low levels of LDL cholesterol and a substantially reduced risk of CHD. 34 As interaction between PCSK9 and the LDL receptor (LDLR) triggers the intracellular degradation of the LDLR, lower levels of circulating PCSK9 result in higher expressions of LDLRs and therefore in a reduction of circulating LDL cholesterol levels. 35 In addition, a recent study showed that circulating levels of PCSK9 are associated with outcome in patients after ACS. 36 A profound and persistent reduction of LDL cholesterol levels by up to approximately 60% was confirmed by numerous studies with different monoclonal antibodies against PCSK9. 11, 12, 37, 38 Alirocumab and evolocumab are two PCSK9 antibodies already approved and in clinical use in Europe. One post hoc analysis (with alirocumab) and one prespecified exploratory analysis (with evolocumab) both reported a reduction of major adverse cardiovascular events associated with the use of a PCSK9 inhibitor. 11, 12 Furthermore, the results of FOURIER, a randomised, double-blind, and placebo controlled trial investigating whether further lowering of LDL cholesterol using a PCSK9 inhibitor reduces cardiovascular events in patients at very high cardiovascular risk, have recently been published: 27,564 patients with evident atherosclerotic disease and LDL cholesterol of 70 mg/dL or greater despite statin therapy (preferably high-intensity statin therapy), with or without ezetimibe, were randomly assigned to receive either evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. Over a median follow-up of 2.2 years evolocumab treatment, compared with placebo, significantly reduced the primary efficacy endpoint (composite of cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation) by 15% (9.8 vs. 11.3%, P < 0.001). The key secondary efficacy endpoint (composite of cardiovascular death, myocardial infarction or stroke) was significantly reduced by 20% (5.9 vs. 7.4%, P < 0.001). Injection-site reactions were more common with evolocumab, but with regard to other adverse events (including neurocognitive events) there was no significant difference between the study groups. 14 These findings suggest that patients at very high cardiovascular risk can benefit from lowering LDL cholesterol even below current targets. Another long-term outcome study on the safety and efficacy of a PCSK9 inhibitor (alirocumab) in patients at high and very high cardiovascular risk is currently ongoing. 39 Meanwhile, current European guidelines have introduced PCSK9 inhibition as a class IIb recommendation in patients at very high cardiovascular risk, with persistently high levels of LDL cholesterol despite treatment with the maximal tolerated statin dose, in combination with ezetimibe or in patients with statin intolerance. 5 In addition, a task force of the European Society of Cardiology and the European Atherosclerosis Society recently issued a more detailed consensus document, discussing and recommending the appropriate clinical use of PCSK9 antibodies in patients at very high cardiovascular risk. 40 In summary, the task force recommends consideration of a PCSK9 inhibitor treatment in:
. Patients at very high cardiovascular risk (i.e. patients with documented atherosclerotic cardiovascular disease and patients with diabetes mellitus and target organ damage or with a major risk factor), who despite recommended maximally tolerated statin plus ezetimibe therapy require more than 50% reduction in LDL cholesterol levels (i.e. with LDL cholesterol levels >3.6 mmol/L or >140 mg/dL) to reach the recommended goal (<1.8 mmol/L or <70 mg/dL). . Severe familial hypercholesterolaemia patients with atherosclerotic cardiovascular disease, as well as those without atherosclerotic cardiovascular disease and LDL cholesterol levels greater than 5.0 mmol/L or greater than 2000 mg/dL despite recommended maximally tolerated statin plus ezetimibe therapy. . Patients at very high cardiovascular risk (see above)
intolerant of at least two statins at any dose, with muscle symptoms and/or creatine kinase elevation, and with substantially elevated LDL cholesterol levels despite ezetimibe therapy.
Attaining LDL-cholesterol goals: the reality As discussed above, lowering LDL cholesterol to the goal of less than 1.8 mmol/L (<70 mg/dL) or achieving 50% or greater LDL cholesterol reduction when this goal cannot be reached is a class IA recommendation in current guidelines. 5 In this context, data from registries in Canada and Europe are worrying, because only 35-40% of these registry patients with ACS or stable CHD attain the LDL cholesterol treatment goal. Furthermore, real-world treatment goal attainment may even be substantially lower: the EUROASPIRE investigators gathered CHD patients' data from 79 centres in 24 European countries. A total of 6648 patients were surveyed 6-36 months after hospitalisation for a CHD event (coronary artery bypass grafting, percutaneous coronary intervention, acute myocardial infarction, acute myocardial ischaemia). Statin therapy had been discontinued in 11.6% and only 19.3% of all CHD patients had LDL cholesterol levels below the target value of 1.8 mmol/L (70 mg/dL) at the time of the interview. 41 The benefit of lipid-lowering treatment seen in studies and recommended in the European guidelines on cardiovascular prevention will only be fully implemented in real life if patients are treated appropriately and adhere to the prescribed LDL cholesterol-lowering strategy. Obviously, many patients at very high cardiovascular risk are still not adequately treated, failing to attain LDL cholesterol target values. More efficient LDL cholesterol lowering will potentially lead to a further reduction of CHD mortality and morbidity.
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